CER Daily Newsfeed

Potential Solutions to Remove Barriers to Gene Therapies

(11/22, Laura Joszt, MA, Managed Healthcare Executive) reports “Like many novel therapies, gene therapies are not without challenges that can be solved through a combination of policy and market changes. In order to improve patient access to these life-saving therapies new payment solutions, education efforts around the availability of these treatments and their benefits and risks, and the use of appropriate value assessment methods are all needed, according to a white paper from the National Pharmaceutical Council (NPC).” Full

Increasing the Longevity of Accountability, Designing Cooperative Models, and Transferring Risk Across a Lifetime of Accountable Care

(11/21, Travis Broome, MPH, MBA, The American Journal of Managed Care) comments “...Cooperation in the design of ACO models, commonality in how the different types of risk are transferred or more often not transferred to ACOs, and the constant improvement of our predictive risk models will lead to accountable care that flourishes in the multipayer system we have in America. It will be difficult because everyone’s best design will be slightly different from everyone else’s best design. Financial alignment will never be perfect in any singular year. Yet the benefits of everyone moving closer together to a model that creates sustainable revenue based on primary care outcomes can last a lifetime.” Full

England’s Funding Rejection For Enhertu At Odds With 19 European Countries

(11/22, Eliza Slawther, Pink Sheet) reports “...NICE, England’s health technology assessment institute, says it was unable to reach a price agreement for AstraZeneca/Daiichi Sankyo’s HER2-low breast cancer drug Enhertu, breaking a line of 21 positive recommendations for breast cancer therapies.” Subscription Required

EU Regulators Eye Social Media For Real-World Data Insights

(11/22, Vibha Sharma, Pink Sheet) reports “...As drug companies continue to explore the use of social media data to support their submissions, a panel of EU regulators have drawn up a seven-point action plan to help evaluate the usefulness and impact of such data in regulatory decision-making.” Subscription Required